RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Duarte, CA · La Jolla, CA · Los Angeles, CA · +20 more sites
Breast Cancer clinical trials in Los Angeles, CA
48 recruiting breast cancer studies with a site in Los Angeles, CA.
RecruitingPhase 1NCT06545331
Study of XB010 in Subjects With Solid Tumors
Sponsor: Exelixis
Irvine, CA · Los Angeles, CA · +14 more sites
RecruitingPhase 3NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sponsor: Merck Sharp & Dohme LLC
Duarte, CA · Irvine, CA · Los Angeles, CA · +36 more sites
RecruitingPhase 3NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sponsor: Eli Lilly and Company
Clovis, CA · Duarte, CA · Emeryville, CA · +126 more sites
RecruitingPhase 1 / Phase 2NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor: Genmab
Los Angeles, CA · San Diego, CA · Santa Barbara, CA · +34 more sites
RecruitingPhase 3NCT06790693
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Sponsor: Hoffmann-La Roche
Burbank, CA · Irvine, CA · La Jolla, CA · +59 more sites
RecruitingPhase 1NCT06840886
A Study of PHST001 in Advanced Solid Tumors
Sponsor: Pheast Therapeutics
Beverly Hills, CA · Los Angeles, CA · Palo Alto, CA · +17 more sites
RecruitingPhase 3NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Beverly Hills, CA · Duarte, CA · Los Angeles, CA · +49 more sites
RecruitingPhase 1NCT05877599
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Sponsor: AstraZeneca
Duarte, CA · Los Angeles, CA · Newport Beach, CA · +17 more sites
RecruitingPhase 3NCT05646862
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Sponsor: Hoffmann-La Roche
Greenbrae, CA · Los Alamitos, CA · Los Angeles, CA · +36 more sites
RecruitingPhase 1 / Phase 2NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Sponsor: Astellas Pharma Global Development, Inc.
Los Angeles, CA · +17 more sites
RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Bakersfield, CA · Berkeley, CA · Beverly Hills, CA · +173 more sites
RecruitingPhase 1NCT06440005
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Sponsor: Angiex, Inc.
Los Angeles, CA · +6 more sites
RecruitingPhase 3NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor: NRG Oncology
Anaheim, CA · Antioch, CA · Arroyo Grande, CA · +1223 more sites
RecruitingPhase 3NCT06072612
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Sponsor: BriaCell Therapeutics Corporation
Anaheim, CA · Bakersfield, CA · Beverly Hills, CA · +76 more sites
RecruitingPhase 1NCT07216105
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Sponsor: Fate Therapeutics
La Jolla, CA · Los Angeles, CA · +3 more sites
RecruitingPhase 1NCT06582017
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Sponsor: Nammi Therapeutics Inc
Los Angeles, CA · +7 more sites
RecruitingPhase 1 / Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Clovis, CA · Los Angeles, CA · Newport Beach, CA · +8 more sites
RecruitingPhase 1NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
Sponsor: MacroGenics
Los Angeles, CA · +6 more sites
RecruitingPhase 3NCT05232916
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Sponsor: Greenwich LifeSciences, Inc.
Duarte, CA · Fullerton, CA · Irvine, CA · +48 more sites
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Arroyo Grande, CA · Berkeley, CA · +825 more sites
RecruitingPhase 1 / Phase 2NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Sponsor: Daiichi Sankyo
Los Angeles, CA · Whittier, CA · +15 more sites
RecruitingEarly Phase 1NCT06123286
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Sponsor: Philip Chang
Los Angeles, CA · Torrance, CA
RecruitingPhase 3NCT06748222
E-Mindfulness Approaches for Living After Breast Cancer
Sponsor: NRG Oncology
Anaheim, CA · Antioch, CA · Bakersfield, CA · +378 more sites
RecruitingPhase 2NCT07017673
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Sponsor: Cedars-Sinai Medical Center
Los Angeles, CA · Pasadena, CA · +1 more sites
RecruitingPhase 1NCT06562192
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Sponsor: Novartis Pharmaceuticals
Los Angeles, CA · Palo Alto, CA · +7 more sites
RecruitingPhase 1NCT07524322
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Sponsor: Regor Pharmaceuticals Inc.
Los Angeles, CA · +4 more sites
RecruitingPhase 2NCT05595499
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
Sponsor: Jonsson Comprehensive Cancer Center
Alhambra, CA · Beverly Hills, CA · Burbank, CA · +4 more sites
RecruitingPhase 1 / Phase 2NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Los Angeles, CA · San Francisco, CA · +26 more sites
RecruitingPhase 1NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Anaheim, CA · Fullerton, CA · +103 more sites
RecruitingPhase not listedNCT05786664
Breast Cancer Survivorship Biorepository
Sponsor: University of Southern California
Los Angeles, CA
RecruitingPhase not listedNCT02250352
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Sponsor: University of Southern California
Los Angeles, CA
RecruitingNot applicableNCT05190978
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
Sponsor: University of California, Los Angeles
Los Angeles, CA
RecruitingPhase 3NCT04852887
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sponsor: NRG Oncology
Anaheim, CA · Antioch, CA · Arroyo Grande, CA · +809 more sites
RecruitingPhase 1 / Phase 2NCT04333706
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
Sponsor: University of Southern California
Los Angeles, CA · +1 more sites
RecruitingPhase 3NCT06435429
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Sponsor: Jazz Pharmaceuticals
Cerritos, CA · Glendale, CA · Los Angeles, CA · +45 more sites
RecruitingPhase 1 / Phase 2NCT06926920
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Sponsor: Gilead Sciences
Los Angeles, CA · +8 more sites
RecruitingPhase 2NCT03804944
Converting HR+ Breast Cancer Into an Individualized Vaccine
Sponsor: Weill Medical College of Cornell University
Los Angeles, CA · +7 more sites
RecruitingNot applicableNCT07208084
Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer
Sponsor: University of California, Los Angeles
Los Angeles, CA
RecruitingPhase 1 / Phase 2NCT06943521
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Sponsor: Tanabe Pharma America, Inc.
Los Angeles, CA · +3 more sites
RecruitingPhase 2NCT04553770
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Sponsor: Jonsson Comprehensive Cancer Center
Fullerton, CA · Los Alamitos, CA · Los Angeles, CA · +6 more sites
RecruitingPhase 3NCT05929768
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Sponsor: SWOG Cancer Research Network
Anaheim, CA · Arroyo Grande, CA · +952 more sites
RecruitingPhase 1 / Phase 2NCT06827613
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Sponsor: Marengo Therapeutics, Inc.
Los Angeles, CA · +4 more sites
RecruitingPhase 1NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
Sponsor: Nurix Therapeutics, Inc.
Duarte, CA · Los Angeles, CA · San Francisco, CA · +7 more sites
RecruitingPhase 1 / Phase 2NCT06682793
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Sponsor: A2 Biotherapeutics Inc.
La Jolla, CA · Los Angeles, CA · +8 more sites
RecruitingPhase 1 / Phase 2NCT04503265
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Sponsor: AtlasMedx, Incorporated
Los Angeles, CA · +3 more sites
RecruitingPhase not listedNCT02253251
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Sponsor: MiraKind
Los Angeles, CA
Not yet recruitingPhase 2NCT07015853
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Sponsor: Stephen Shiao
Los Angeles, CA
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.